Outstanding Benefits for Patients

DIFFICULT CANCERS REQUIRE SMARTER STRATEGIES

  • Tumors have latent vulnerabilities that can be identified through ETA.
  • Agnostic to stage, grade, anatomy or morphology.
  • Integrational multi-analyte interrogation of tumor interactome and tumor function.
  • Tandem targeting of multiple vulnerabilities of the tumor using combination therapies to yield additive or synergistic benefits.

Who will Benefit

First-line therapy has failed.
Risk of therapy failure is high.
Cancer has relapsed.
For newly diagnosed patients to explore best therapy options.
Cancer is high-grade / metastatic.

See the Results for Yourself

Patients who have not benefited from chemo-therapy require ultra-personalized treatment. We specialize in providing guidance for difficult cases by using highly sophisticated molecular analysis technology. We have a clinically proven track record of extremely high success.

Presentation

Conventional versus Modern

Why Exacta®

Exacta® is an intensive and in depth tumor gene expression analysis. It analyses 100s of millions of data points at the molecular level to reveal all possible targets for precision drugs. Exacta® is one of the most powerful tumor investigation and is an extreme analytical tool that reveals the driven mutations and pathways driving a personʼs cancer. Exacta® is best molecular analysis for difficult cancers.

Features

Determines deepest genetic facets of an individual patientʼs cancer.
Accurate, multi-coordinate analysis of all 22,000 genes in the cancer genome.
Reaches the depths of cancerʼs mechanism through 100ʼs of millions of data points.
Reveals mutations and pathways that are propelling a particular cancer in an individual.
Enables a highly sophisticated treatment strategy beyond conventional perspective.

Clinically Validated (Publications)

The validation data for Exacta® / The resilient protocol has been extensively published in leading peer reviewed journals.

Publications

FREQUENTLY ASKED QUESTIONS

What is therapy recommendation?

During Exacta® analysis, the samples submitted by the patient (e.g., fresh tissue, FFPE blocks, blood, fluids) are analysed to identify vulnerabilities of cancer, for which various drugs may exist. Based on the established efficacy and safety profile, a preference list of these drugs (single drug or combinations) is assigned for each patient. This is therapy recommendation and is included as an integral part of every Exacta® report.

If two patients have the same histopathological cancer type, and one of them undergoes Exacta® analysis, can the other patient receive the same treatment as indicated in the therapy recommendation of the first patient?

How is the therapy recommendation used?

Why is it important to start treatment immediately?

What kind of drugs will be suggested in the therapy recommendation?

Are there any follow-up molecular tests to assess the result of the recommended therapy?

DOWNLOAD BROCHURE + SAMPLE REPORT

PDF will be emailed

 

I have read and understood the terms of use and the privacy policy and I agree.

CONTACT US

Please fill in the contact inquiry form below. We will get back to you shortly by email. Thank you!

I have read and understood the terms of use and the privacy policy and I agree.



7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
3
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index